Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19104


Purpose:

The purpose of this study is to demonstrate comparability between Contour SE™ Microspheres and Embosphere® Microspheres for achieving post UFE fibroid devascularization in women with symptomatic uterine fibroids.


Study summary:

The purpose of this prospective randomized single-center study is to demonstrate comparability using Contour SE™ Microspheres (700-900µ and 900-1200µ) using a near stasis endpoint and Embosphere® Microspheres (500-700µ) using a "prune tree" endpoint for achieving post UFE fibroid devascularization in women with symptomatic uterine fibroids. The study will demonstrate (with the use of contrast enhanced Magnetic Resonance Imaging (MRI) at baseline and 24-hours post embolization) that uterine fibroids can successfully be devascularized using the embolization protocols. Contrast enhanced MRI will be performed at baseline, 24-hours, and 3-months post UFE. The subjects will be followed through 12-months post UFE and change from baseline in symptom severity (Quality of Life (QoL) Questionnaire) will be assessed at 3 months and 12 months.


Criteria:

Inclusion Criteria: - One or more of the following symptoms: abnormal menstrual bleeding, infertility related to fibroids, pelvic pain, and/or bulk/pressure related symptoms attributed to fibroids: i.e., pelvic pressure, abdominal enlargement, abdominal bloating, gastrointestinal pressure symptoms (backache, constipation), dysfunction of the urinary bladder (urinary frequency, urinary retention), vaginal pressure, and rectal pressure. - Severity of the symptom(s) warrants invasive treatment - Willing and able to complete the follow-up requirements outlined in the study design section of the protocol - Willing to sign a consent form Exclusion Criteria: - Active pelvic inflammatory disease or infection - Any malignancy of the pelvic region - Endometrial neoplasia or hyperplasia - Presence of one or more submucosal fibroid(s) with more than 50% growth into the uterine cavity - Presence of pedunculated serosal fibroid as the dominant fibroid(s) - Fibroids with significant collateral feeding by vessels other than the uterine arteries - Presence of arteries supplying the fibroid are not large enough to accept 700-900 micron or 900-1200 micron microspheres - Coagulopathy - Atypical anatomy that will not allow for bilateral UFE - Subject with known severe contrast allergy - Subjects with known moderate to severe renal disease


NCT ID:

NCT00628901


Primary Contact:

Principal Investigator
Richard Shalansky-Goldberg, MD
University of Pennsylvania


Backup Contact:

N/A


Location Contact:

Philadelphia, Pennsylvania 19104
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.